Company Filing History:
1 out of 3 
1 out of 1,746 
1 out of 231 
Years Active: 2020
Title: Sylvie Bouvier: Innovator in Human Fertility Treatment
Introduction: Sylvie Bouvier, based in Nîmes, France, has made significant contributions to the field of human fertility treatment through her innovative research. With a strong background in medical sciences, her work is pivotal in helping couples achieve successful pregnancies.
Latest Patents: Sylvie Bouvier holds a patent titled "Use of soluble CD146 as a biomarker to select in vitro-fertilized embryo for implantation in a mammal." This groundbreaking invention identifies soluble CD146 (sCD146) as a crucial biomarker that, when analyzed in an embryo culture medium, can determine the viability of an embryo for implantation in a mammal’s uterus. This invention provides a valuable tool and related kits for (pre)selecting embryos that are eligible for implantation, thereby improving the success rate of fertility treatments. Additionally, the patent details methods aimed at promoting pregnancy during embryo transfer.
Career Highlights: Throughout her career, Sylvie Bouvier has been associated with esteemed research institutions like the Centre Hospitalier Universitaire de Nîmes and the Institut National de la Santé et de la Recherche Médicale. Her work in these organizations has been instrumental in advancing reproductive health and fertility techniques.
Collaborations: Sylvie has collaborated with notable colleagues, including Nathalie Bardin and Marcel Blot-Chabaud. These partnerships have fostered an environment of innovation and have contributed to the successful development of her patent.
Conclusion: Sylvie Bouvier's dedication to enhancing human fertility through innovative research underscores the importance of scientific advancements in reproductive medicine. Her contributions, highlighted by her patent, shine a light on the potential for improved outcomes in fertility treatments, bringing hope to many aspiring families.